ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b5 reductase and/or cytochrome b5 in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b5 reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyellipticine and the ellipticine N2-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. Using the 32P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyellipticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome b5 stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome b5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b5 can act as an allosteric modifier of the CYP3A4 oxygenase.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London SE1 9NH UK

Department of Biochemistry Faculty of Science Charles University Albertov 2030 128 40 Prague 2 Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague 5 Czech Republic

Department of Pediatric Hematology and Oncology 2nd Medical Faculty Charles University and University Hospital Motol 5 Uvalu 84 150 06 Prague 5 Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

Laboratory of Metallomics and Nanotechnology Department of Chemistry and Biochemistry Mendel University in Brno Zemedelska 1 61300 Brno Czech Republic

Zobrazit více v PubMed

Auclair C. Arch Biochem Biophys. 1987;259:1. doi: 10.1016/0003-9861(87)90463-2. PubMed DOI

Stiborová M, Bieler CA, Wiessler M, Frei E. Biochem Pharmacol. 2001;62:1675. doi: 10.1016/S0006-2952(01)00806-1. PubMed DOI

Stiborová M, Bořek-Dohalská L, Aimová D, Kotrbová V, Kukačková K, Janouchová K, Rupertová M, Ryšlavá H, Hudeček J, Frei E. Gen Physiol Biophys. 2006;25:245. PubMed

Stiborová M, Rupertová M, Frei E. Biochim Biophys Acta. 2011;1814:175. doi: 10.1016/j.bbapap.2010.05.016. PubMed DOI

Stiborová M, Černá V, Moserová M, Mrízová I, Arlt VM, Frei E. Int J Mol Sci. 2015;16:284. doi: 10.3390/ijms16010284. PubMed DOI PMC

Garbett NC, Graves DE. Curr Med Chem Anti-Cancer Agents. 2004;4:149. doi: 10.2174/1568011043482070. PubMed DOI

Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E, Stiborova M. Pharmacol Ther. 2012;133:26. doi: 10.1016/j.pharmthera.2011.07.006. PubMed DOI

Stiborova M, Frei E. Current Med Chem. 2014;21:575. doi: 10.2174/09298673113206660272. PubMed DOI

Tmejova K, Krejcova L, Hynek D, Adam V, Babula P, Trnkova L, Stiborova M, Eckschlager T, Kizek R. Anti-Cancer Age Med. 2014;14:331. doi: 10.2174/18715206113139990316. PubMed DOI

Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. Chem Res Toxicol. 2003;16:38. doi: 10.1021/tx0200818. PubMed DOI

Stiborova M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E. Cancer Res. 2004;64:8374. doi: 10.1158/0008-5472.CAN-04-2202. PubMed DOI

Stiborova M, Poljaková J, Ryšlavá H, Dračínský M, Eckschlager T, Frei E. Int J Cancer. 2007;120:243. doi: 10.1002/ijc.22247. PubMed DOI

Stiborova M, Rupertová M, Aimová D, Ryšlavá H, Frei E. Toxicology. 2007;236:50. doi: 10.1016/j.tox.2007.03.026. PubMed DOI

Stiborova M, Arlt VM, Henderson CJ, Wolf CR, Kotrbova V, Moserova M, Hudecek J, Phillips DH, Frei E. Toxicol Appl Pharmacol. 2008;226:318. doi: 10.1016/j.taap.2007.09.017. PubMed DOI

Stiborova M, Indra R, Moserova M, Cerna V, Rupertova M, Martinek V, Eckschlager T, Kizek R, Frei E. Chem Res Toxicol. 2012;25:1075. doi: 10.1021/tx3000335. PubMed DOI

Stiborova M, Poljakova J, Martínkova E, Ulrichova J, Simanek V, Dvorak Z, Frei E. Toxicology. 2012;302:233. doi: 10.1016/j.tox.2012.08.004. PubMed DOI

Kotrbova V, Mrazova B, Moserova M, Martinek V, Hodek P, Hudecek J, Frei E, Stiborova M. Biochem Pharmacol. 2011;82:669. doi: 10.1016/j.bcp.2011.06.003. PubMed DOI

Pandey AV, Flück CE. Pharmacol Ther. 2013;138:229. doi: 10.1016/j.pharmthera.2013.01.010. PubMed DOI

Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR. Mol Pharmacol. 2015;87:733. doi: 10.1124/mol.114.097394. PubMed DOI

Indra R, Moserova M, Sulc M, Frei E, Stiborova M. Neuro Endocrinol Lett. 2013;34(Suppl 2):55. PubMed

Guengerich FP. Chem Res Toxicol. 2008;21:70. doi: 10.1021/tx700079z. PubMed DOI

Porter TD. J Biochem Mol Toxicol. 2002;16:311. doi: 10.1002/jbt.10052. PubMed DOI

Schenkman JB, Jansson I. Pharmacol Ther. 2003;97:139. doi: 10.1016/S0163-7258(02)00327-3. PubMed DOI

McLaughin LA, Ronseaux S, Finn RD, Henderson CJ, Wolf CR. Mol Pharmacol. 2010;75:269. doi: 10.1124/mol.110.064246. PubMed DOI

Baron J, Hildebrandt AG, Peterson JA, Estabrook RW. Drug Metab Dispos. 1973;1:129. PubMed

Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP. J Biol Chem. 1996;271:27438. doi: 10.1074/jbc.271.44.27438. PubMed DOI

Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, Yokoi T. Drug Metab Dispos. 1999;27:999. PubMed

Yamazaki H, Shimada T, Martin MV, Guengerich FP. J Biol Chem. 2001;276:30885. doi: 10.1074/jbc.M105011200. PubMed DOI

Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T. Protein Expr Purif. 2002;24:329. doi: 10.1006/prep.2001.1578. PubMed DOI

Lamb DC, Kaderbhai NN, Venkateswarlu K, Kelly DE, Kelly SL, Kaderbhai MA. Arch Biochem Biophys. 2001;395:78. doi: 10.1006/abbi.2001.2566. PubMed DOI

Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita KI, Kamataki T. Biochem Pharmacol. 2003;66:2333. doi: 10.1016/j.bcp.2003.08.004. PubMed DOI

Akhtar MK, Kelly SL, Kaderbhai MA. J Endocrinol. 2005;187:267. doi: 10.1677/joe.1.06375. PubMed DOI

Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ, Wolf CR. J Biol Chem. 2008;283:31385. doi: 10.1074/jbc.M803496200. PubMed DOI PMC

Henderson CJ, McLaughlin LA, Wolf CR. Mol Pharmacol. 2013;83:1209. doi: 10.1124/mol.112.084616. PubMed DOI

Henderson CJ, McLaughlin LA, Finn RD, Ronseaux S, Kapelyukh Y, Wolf CR. Drug Metab Dispos. 2014;42:70. doi: 10.1124/dmd.113.055277. PubMed DOI PMC

Gilep AA, Guryev OL, Usanov SA, Estabrook RW. J Inorg Biochem. 2001;87:237. doi: 10.1016/S0162-0134(01)00333-6. PubMed DOI

Inui H, Maeda A, Ohkawa H. Biochemistry. 2007;46:10213. doi: 10.1021/bi700164q. PubMed DOI

Lee SJ, Goldstein JA. Drug Metab Pharmacokinet. 2012;27:663. doi: 10.2133/dmpk.DMPK-12-SH-030. PubMed DOI PMC

Stiborová M, Indra R, Moserová M, Šulc M, Hodek P, Frei E, Schmeiser HH, Arlt V. Monatsh Chem. 2016;147:847. doi: 10.1007/s00706-016-1713-y. PubMed DOI PMC

Stiborová M, Indra R, Moserová M, Frei E, Schmeiser HH, Kopka K, Phillips DH, Arlt VM. Chem Res Toxicol. 2016;29:1325. doi: 10.1021/acs.chemrestox.6b00143. PubMed DOI PMC

Mrízová I, Moserová M, Milichovský J, Šulc M, Kizek R, Kubáčková K, Arlt VM, Stiborová M. Monatsh Chem. 2016;147:881. doi: 10.1007/s00706-016-1738-2. PubMed DOI PMC

Stiborová M, Moserová M, Mrízová I, Dračínská H, Martínek V, Indra R, Frei E, Adam V, Kizek R, Schmeiser HH, Kubáčková K, Arlt VM. Monatsh Chem. 2016;147:897. doi: 10.1007/s00706-015-1636-z. PubMed DOI PMC

Borek-Dohalska L, Frei E, Stiborová M. Collect Czech Chem Commun. 2004;69:603. doi: 10.1135/cccc20040603. DOI

Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J, Stiborová M. Cancer Lett. 2007;252:270. doi: 10.1016/j.canlet.2006.12.037. PubMed DOI

Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Martínek V, Kizek R, Stiborová M. Biochem Pharmacol. 2009;77:1466. doi: 10.1016/j.bcp.2009.01.021. PubMed DOI

Martinkova E, Dontenwill M, Frei E, Stiborova M. Neuro Endocrinol Lett. 2009;30(Suppl 1):60. PubMed

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. Int J Cancer. 2003;107:885. doi: 10.1002/ijc.11511. PubMed DOI

Antley R, Bixler D. Birth Defects Orig Artic Ser. 1975;11:397. PubMed

Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Drug Metab Dispos. 2012;40:754. doi: 10.1124/dmd.111.042820. PubMed DOI PMC

Borek-Dohalská L, Hodek P, Sulc M, Stiborová M. Chem Biol Interact. 2001;138:85. doi: 10.1016/S0009-2797(01)00263-0. PubMed DOI

Borek-Dohalská L, Stiborová M. Collect Czech Chem Commun. 2010;75:201. doi: 10.1135/cccc2009525. DOI

Schmeiser HH, Stiborova M, Arlt VM. Methods Mol Biol. 2013;1044:389. doi: 10.1007/978-1-62703-529-3_21. PubMed DOI

Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity

Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation

Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine

The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells